Related Experiment Video
Updated: Sep 10, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Upadacitinib Monotherapy for Treatment of Pyoderma Gangrenosum
Mohamad R Taha1, Harrison P Nguyen2, Stephen K Tyring2,3
1College of Medicine, Texas A&M University Health Science Center, Bryan, Texas.
Pyoderma gangrenosum (PG) is a painful skin ulcer condition. This study shows upadacitinib, a Janus kinase (JAK) inhibitor, successfully treated PG patients, offering a new therapeutic option.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Pyoderma gangrenosum (PG) is a rare, ulcerative neutrophilic dermatosis.
- Current treatments lack standardization and often result in recurrence.
- The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is implicated in PG pathogenesis.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Ulcerative Colitis in IBD
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Acute Pyelonephritis II: Diagnostic Studies and Management
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

